Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest ...
Magellan Health, Inc., a Fortune 500 company, i...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Bellicum Pharmaceuticals is a clinical-stage bi...
Guardion Health Sciences is at the forefront of early detection, intervention and ...
Guardion Health Sciences is at the forefront of...
NanoVibronix Inc. is a medical device company that is focused on creating medical ...
NanoVibronix Inc. is a medical device company t...
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology com...
Headquartered in Mountain View, California, IGM...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Join the National Investor Network and get the latest information with your interests in mind.